Hande Sciences

Executive Summary

Hande Sciences is a China-based contract development and manufacturing organization (CDMO) focused on small molecule drug development and manufacturing. Founded in 2020 and headquartered in Suzhou, the company operates a 35,000 square meter facility in Changshu that meets European and US GMP standards. Its capabilities include process development, API manufacturing, safety assessment, and analytical services, serving pharmaceutical and biotech partners globally. With a team of 200-500 employees, Hande Sciences is positioned to capitalize on the growing demand for outsourced drug development and manufacturing in China, particularly in the small molecule space. The company's platform stage and private status suggest it may be seeking to expand its client base and capacity, though specific financial details and pipeline projects are not publicly disclosed. As a relatively young CDMO, Hande Sciences faces opportunities in the expanding Chinese pharmaceutical market, where cost-effective and high-quality manufacturing is in high demand. However, competition from established CDMOs and regulatory hurdles in international markets pose risks. The company's ability to attract blue-chip clients and maintain GMP compliance will be key to its growth. While no proprietary assets or revenue figures are available, the CDMO model typically provides recurring revenue streams. The company's estimated valuation and lack of public funding data imply it may be in early growth stages, with potential for partnerships or capacity additions to drive near-term value.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new manufacturing capacity expansion70% success
• TBDSecuring a long-term supply agreement with a major pharmaceutical company50% success
• Q2 2026Successful completion of a regulatory inspection (e.g., NMPA or FDA) with no major observations85% success